塞里斯制药 XERS

On June 29, 2026, the Board appointed John Shannon, the Company's Chief Executive Officer, to serve as Chairperson of the Board, effective as of July 1, 2026. John Shannon has served on our board of directors and as Chief Executive Officer since August 2024. Previously he served as President and Chief Operating Officer from October 2021 to August 2024. Mr. Shannon joined Xeris Pharmaceuticals, Inc. in February 2017 as Chief Operating Officer and in August 2020, Mr. Shannon was appointed President of Xeris Pharmaceuticals, Inc. as well. Previously, from 2015 until its acquisition in 2016, Mr. Shannon served as chief executive officer and director for Catheter Connections, Inc. Prior to that, from 2012 until its acquisition in 2014, Mr. Shannon served as chief commercial officer for Durata Therapeutics, a biopharmaceutical company. From 2002 to 2012, he served as vice president and general manager of Baxter BioScience, a biopharmaceutical company. Mr. Shannon received a B.S. degree in biology with an emphasis in microbiology from Western Illinois University.

Dr. Nguyen brings an extensive wealth of clinical and leadership experience to his role as CMO, leading the development of first-in-class therapies including circular RNA-based oncology treatments, gene-edited xenotransplants, immuno-oncology vaccines, and allogeneic CAR-T therapies. Dr. Nguyen served as Vice President and Therapeutic Sector Lead at Asklepios Biopharmaceutical (AskBio), where he directed the IND clearance and early-phase clinical trials of AAV gene therapies for neuromuscular rare disease. Among his many achievements, Dr. Nguyen shaped clinical and regulatory policies for breakthrough therapies while serving as a medical officer at the NIH, FDA, and CMS. During his Robert Wood Johnson Foundation Health Policy Fellowship serving on the US Senate HELP Committee, Dr. Nguyen was a key contributor to the landmark 21st Century Cures Act. He also led the establishment of an ambulatory surgical service to expedite pediatric orphan disease and oncology trials, earning the prestigious NIH Director's Award. During his tenure at Xeris, Dr. Nguyen served as the program medical lead for Gvoke's NDA and MAA approvals and multiple IND clearances for endocrine and rare disease, including novel endocrine drug co-formulations for diabetes, immunology, and pediatric epilepsy. Dr. Nguyen received an MBA from University of Chicago, a MD from Rutgers New Jersey Medical School, and completed his residency and fellowship training in anesthesiology and cardiovascular anesthesia at Massachusetts General Hospital, Harvard Medical School. On February 20, 2025, the Board of Directors of the Company approved the appointment of Dr. Anh Nguyen to the newly created role of Chief Medical Officer of the Company, effective February 24, 2025.

Ms. Hecht has served as our Chief Legal Officer and Corporate Secretary since October 2021 in connection with the Strongbridge acquisition. Ms. Hecht joined Xeris Pharmaceuticals, Inc. in January 2018 as Senior Vice President, General Counsel and Corporate Secretary. Ms. Hecht has over thirty years of experience as a corporate executive and attorney in the life sciences industry. From 2012 to 2018, she was managing director and chief legal and administrative officer of Auven Therapeutics, a global biotechnology and pharmaceutical private equity firm. From November 2013 through November 2014, Ms. Hecht also served as corporate secretary and legal and compliance advisor at Durata Therapeutics, a biopharmaceutical company. Prior to that, she was senior vice president, general counsel and corporate secretary at the Sun Products Corporation from March 2009 through September 2012, and prior to that executive vice president and general counsel of MedPointe Healthcare, Inc., a pharmaceutical company. Since March 2021, Ms. Hecht has served on the board of directors of Iterum Therapeutics plc, a clinical stage pharmaceutical company, where she serves on the audit and compensation committees. Additionally, from September 2015 through March 2021, she served on the board of directors for Neos Therapeutics, Inc., a pharmaceutical company, where she chaired the nominating and corporate governance committee. Ms. Hecht received a B.A. from Amherst College in 1985 and a J.D. from Harvard Law School.

Mr. Pieper has served as our Chief Financial Officer since October 2021, in connection with the Strongbridge acquisition. Mr. Pieper joined Xeris Pharmaceuticals, Inc. in February 2017 as Vice President of Finance and was appointed as Chief Financial Officer in July 2021. Previously, from July 2015 to February 2017, Mr. Pieper held roles of increasing responsibility at Catheter Connections, Inc., including most recently as chief financial officer and chief operating officer. Mr. Pieper received a B.S. in finance and an accounting minor from DePaul University and an M.B.A. from the Quinlan School of Business at Loyola University Chicago.

Mr. Brady has served on our board of directors since March 2025. From 1988 to 2018, Mr. Brady served in multiple leadership roles of increasing responsibility for AstraZeneca prior to his retirement in 2018. His more than thirty years of progressive experience at AstraZeneca included successful national, regional and global finance roles in corporate operations, manufacturing, commercial, marketing, market access, audit, international business, and biologics discovery and development. He most recently served as Chief Financial Officer of MedImmune, the biologics discovery and development division of AstraZeneca, from 2013 to 2018. During his tenure at MedImmune, biologics grew to represent more than half of the product development portfolio of AstraZeneca and five biologics were successfully brought to market. From March 2022 to October 2025, Mr. Brady served as a member of the board of directors and as a member of the audit committee of the board of directors of Verona Pharma plc. From October 2021 to February 2025, Mr. Brady served as a director of Panavance Therapeutics, Inc. Mr. Brady is a Certified Public Accountant and previously worked at Arthur Andersen & Company. He holds a B.S. in Accounting from Saint Joseph's University and an MBA from Drexel University.

Ms. Persky has served as chairperson of the board of directors since August 2024, and on our board of directors since October 2021 in connection with the Strongbridge acquisition. Prior to that, Ms. Persky served as a member of the board of directors of Xeris Pharmaceuticals, Inc. beginning in April 2018. Since 2014, Ms. Persky has served as the chief executive officer and president of WOMN LLC, a consulting and coaching organization. From 2005 to 2013, Ms. Persky was senior vice president, general counsel and corporate secretary of Boehringer Ingelheim Corporation, a pharmaceutical company, and prior to that spent 19 years with Baxter International Inc. in both legal and business roles. From October 2021 to February 2025, Ms. Persky served as a director of Panavance Therapeutics, Inc. Ms. Persky has served on the board of directors of Revolo Biotherapeutics Limited since July 2021. Ms. Persky was a director of Boehringer Ingelheim Corporation, a human and animal health pharmaceutical company, from 2007 to 2013 and of CYTYC Corporation (a women's health diagnostic and device company acquired by Hologic Inc.) from 2003 until 2007. Ms. Persky has a B.S.S. degree in speech sciences from Northwestern University and a J.D. from Washington University School of Law. Effective July 1, 2026, Ms. Marla S. Persky resigned from Chairperson of the Board and was appointed as Lead Independent Director

Ms. Halkuff has served on our board of directors since October 2021 in connection with the Strongbridge acquisition. Prior to that, Ms. Halkuff served as a member of the board of directors of Xeris Pharmaceuticals, Inc. beginning in April 2018. Since December 2024, Ms. Halkuff has served as the Founder of Halkuff Enterprises, an independent consulting company, and as Chief Executive Officer of LiviWell, Inc., a women's health company. From December 2021 until March 2024, Ms. Halkuff served as the chief executive officer of Ideal Protein of America, Inc., or Ideal Protein, a weight loss company based in Quebec, Canada. During her tenure, following a voluntary petition for bankruptcy protection under the Companies' Creditors Arrangement Act (Canada) in the Quebec Superior Court in August 2023, Ideal Protein filed a petition for recognition under Chapter 15 of the U.S. Bankruptcy Code with the U.S. Bankruptcy Court in October 2023, resulting in a court-supervised sale of the business. From November 2016 to September 2021, Ms. Halkuff served as the chief commercial officer of TherapeuticsMD, Inc., a pharmaceutical company. Prior to that, Ms. Halkuff held numerous senior level positions at Pfizer Inc., a biopharmaceutical company, and the Pfizer Consumer Healthcare Wellness Organization and was a member of its Consumer Global Leadership Team, including in roles as senior vice president, global wellness, vice president, women's health sales and marketing and senior director, women's health products. Prior to that, Ms. Halkuff was the commercial lead for sales and marketing of the Pfizer Women's Health Division. From 2005 to 2010, Ms. Halkuff was head of global innovation at Weight Watchers International. Ms. Halkuff has a B.A. degree in psychology from the University of Connecticut and an M.B.A. from Pennsylvania State University.

Dr. Sherman has served on our board of directors since October 2021 in connection with the Strongbridge acquisition. Prior to that, Dr. Sherman served as a member of the board of directors of Xeris Pharmaceuticals, Inc. beginning in April 2018. From June 2009 until November 2023, Dr. Sherman served as the chief medical officer and executive vice president at Horizon Therapeutics plc., a biopharmaceutical company, now Amgen (Rare Disease). Dr. Sherman also served on the board of directors of Strongbridge prior to its acquisition by Xeris Pharmaceuticals, Inc. from October 2016 until October 2021. He has served on the board of directors of Larimar Therapeutics since October 2023 and of Sorriso Pharmaceuticals, Inc. since May 2022. He is a member of a number of professional societies, a diplomat of the National Board of Medical Examiners and the American Board of Internal Medicine, and on the Board of Advisors of the Center for Information and Study on Clinical Research Participation. Additionally, Dr. Sherman served previously on the Board of Directors of the Biotechnology Innovation Organization (BIO). He previously held positions at pharmaceutical companies such as IDM Pharma, Inc., Takeda Global Research and Development, NeoPharm Inc., G.D. Searle, LLC/Pharmacia Corporation, and BristolMyers Squibb, and is a past board chair of the Drug Information Association. Dr. Sherman received a B.A. in Biology from Lake Forest College and earned his M.D. from the Rosalind Franklin University of Medicine and Science/The Chicago Medical School. Dr. Sherman completed internship and residency programs at Northwestern University Feinberg School of Medicine, where he currently serves as an adjunct assistant professor, and a fellowship program at the University of California San Francisco. On April 20, 2026, Dr. Jeffrey Sherman, a member of the Board of Directors of Xeris Biopharma Holdings, Inc., provided notice to the Company of his decision to retire from the Board and not stand for reelection at the Company's 2026 Annual Meeting of Stockholders.

Mr. Johnson has served on our board of directors since October 2021 in connection with the Strongbridge acquisition. Prior to that, Mr. Johnson had served on the board of directors of Strongbridge from March 2015, and as the Chief Executive Officer of Strongbridge from July 2020 to October 2021. Previously, Mr. Johnson served as the Executive Chairman of Applied Therapeutics, Inc. (acquired by Cycle Pharmaceuticals Ltd), a then publicly traded clinical stage biopharmaceutical company, from December 2024 to November 2025. Mr. Johnson served as a director of Reaction Biology Corp., a biotechnology company, from March 2022 to March 2025, and previously served as its Chief Executive Officer from March 2022 until December 2024. Mr. Johnson served as a board member of Melinta Pharmaceuticals, Inc. from July 2009 through September 2019, having served as Chief Executive Officer from February 2019 through August 2019 and as interim Chief Executive Officer from October 2018 until February 2019. Mr. Johnson has also been a member of the board of directors of Verastem, Inc. (also known as Verastem Oncology) since April 2020 and a member of the board of directors of AxoGen, Inc. since July 2021. From January 2012 until August 2014, Mr. Johnson served as the President and Chief Executive Officer of Dendreon Corporation and as its Chairman from January 2012 until June 2014. From January 2011 until January 2012, he served as the Chief Executive Officer and a member of the board of Savient Pharmaceuticals, Inc. From November 2008 until January 2011, From September 2009 to July 2011, Mr. Johnson served as Senior Vice President and President of Eli Lilly and Company's Oncology unit. He was also Chief Executive Officer of ImClone Systems Incorporated, which develops targeted biologic cancer treatments, from August 2007 until November 2008, and served on ImClone's board of directors until it was acquired by Eli Lilly in November 2008. From 2005 to 2007, Mr. Johnson served as Company Group Chairman of Johnson & Johnson's Worldwide Biopharmaceuticals unit, President of its Ortho Biotech Products LP and Ortho Biotech Canada units from 2003 to 2005, and Worldwide Vice President of its CNS, Pharmaceuticals Group Strategic unit from 2001 to 2003. Prior to joining Johnson & Johnson, he also held several executive positions at Parkstone Medical Information Systems, Inc. (from 2000 to 2001), OrthoMcNeil Pharmaceutical Corporation (from 1993 to 2000) and Pfizer, Inc. (from 1983-1988). He also served as a director of various pharmaceutical corporations including Autolus Therapeutics from September 2021 to March 2024, Histogenics Corporation from November 2013 to February 2019, AVEO Pharmaceuticals, Inc. from February 2018 to February 2019, and Portola Pharmaceuticals, Inc. from March 2014 to July 2020. From January 2013 to August 2014, he served as a member of the board of directors for the Pharmaceutical Research and Manufacturers of America. Mr. Johnson also served on the Health Section Governing Board of Biotechnology Industry Organization from January 2013 to August 2014. Mr. Johnson holds a B.S. from the East Stroudsburg University of Pennsylvania.

On June 29, 2026, the Board of Directors of Xeris Biopharma Holdings, Inc. appointed Nerissa Kreher, M.D. effective as of July 1, 2026. Since January 2025, Dr. Kreher has served as Chief Medical Officer of Alltrna, an RNA (tRNA) platform company. Additionally, since July 2024, she has served as the Founder of Mountainview Clinical Development Consulting, a specialized advisory firm, where she provides fractional clinical development, medical affairs, and regulatory strategy services to early-stage biotech and life sciences companies. From March 2024 to December 2024, Dr. Kreher served as an interim Chief Medical Officer for Lucy Therapeutics and also was a clinical development consultant for several rare disease biotechnology companies. Prior to that, she served as Chief Medical Officer of Entrada Therapeutics, a publicly traded biotechnology company, from December 2020 to February 2024. She also held Chief Medical Officer roles at Tiburio Therapeutics (from March 2019 to December 2020) and AVROBIO (acquired by Tectonic Therapeutics) (from October 2016 to December 2018), where she oversaw clinical development for multiple gene therapy programs. Earlier in her career, she served as Global Head (VP) of Clinical and Medical Affairs at Zafgen (from March 2015 to July 2016) and held key roles at Shire (from April 2013 to March 2015) and Enobia Pharma (January 2011 until its acquisition by Alexion Pharmaceuticals in 2012). Following the acquisition, Dr. Kreher served as Executive Director, Metabolic Disorders at Alexion Pharmaceuticals until April 2013. Dr. Kreher has been an independent board member of Rezolute, Inc., a publicly traded biotechnology company, since March 2021. Dr. Kreher holds an M.D. from East Carolina University School of Medicine, an M.S. in Clinical Research from Indiana University, an Executive M.B.A. from Northeastern University, and a B.S. in Biology from University of North Carolina at Chapel Hill.